Catabasis Pharmaceuticals Earning Date (CATB)

USA |NASDAQ |USD

CATB Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 8, 2022 Jun 2022 - - $-5.34
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 8, 2022 Jun 2022 - - $0.00

Catabasis Pharmaceuticals's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.

CATB Earnings Date & History Chart

CATB Earnings & Revenue Forecast

CATB Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $-3.04 $-3.90 $-2.45

CATB Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-3.04 $-0.57 $-0.77

CATB Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $0.00 $0.00 $0.00

CATB Earnings Date & Revenue History

CATB Earnings History

|
Show More
Show More

CATB Revenue History

|
Show More
Show More

Catabasis Pharmaceuticals Next Earnings Date & Report

CATB Next Earnings Date & Report Preview: Jun 2022 (FQ)

CATB's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.

Catabasis Pharmaceuticals Previous Earnings Dates & Reports

CATB Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Catabasis Pharmaceuticals's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

CATB Previous Earnings Date & Report Recap: Dec 2020 (FY)

Catabasis Pharmaceuticals's previous annual earnings date was Mar 11, 2021 for its fiscal year ended Dec 31, 2020.

CATB's earnings per share (EPS) was $-12.18, missing the consensus analysts forecast of $-2.01 by 505.97% , and higher than the previous year's EPS (Dec 2019) by -13.62%.

Revenues were $0.00.

The company reported a net income of $-37.30M.

Catabasis Pharmaceuticals reported a free cash flow of $-32.52M for its fiscal year, compared to $-26.58M a year ago.

The company ended the fiscal year with $1.05M in total debt, a decrease of -53.57% compared to the previous year.